Danaher Corporation $DHR Shares Sold by Reynders McVeigh Capital Management LLC

Reynders McVeigh Capital Management LLC reduced its stake in Danaher Corporation (NYSE:DHR) by 5.7% in the second quarter, HoldingsChannel.com reports. The fund owned 214,788 shares of the conglomerate’s stock after selling 13,039 shares during the quarter. Danaher accounts for 2.1% of Reynders McVeigh Capital Management LLC’s portfolio, making the stock its 15th biggest position. Reynders McVeigh Capital Management LLC’s holdings in Danaher were worth $42,429,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also made changes to their positions in the company. Vanguard Group Inc. increased its holdings in shares of Danaher by 1.3% in the 2nd quarter. Vanguard Group Inc. now owns 60,769,587 shares of the conglomerate’s stock worth $12,004,424,000 after acquiring an additional 788,499 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in shares of Danaher by 3.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate’s stock valued at $4,016,404,000 after buying an additional 612,154 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Danaher by 0.6% during the second quarter. Geode Capital Management LLC now owns 13,726,194 shares of the conglomerate’s stock worth $2,697,800,000 after buying an additional 81,670 shares during the period. Norges Bank bought a new position in Danaher in the 2nd quarter worth approximately $1,979,503,000. Finally, Generation Investment Management LLP increased its position in Danaher by 56.2% in the 2nd quarter. Generation Investment Management LLP now owns 4,965,646 shares of the conglomerate’s stock valued at $980,914,000 after acquiring an additional 1,787,522 shares during the period. Institutional investors own 79.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on DHR. Royal Bank Of Canada set a $241.00 price objective on shares of Danaher in a report on Tuesday, September 2nd. Weiss Ratings restated a “hold (c-)” rating on shares of Danaher in a report on Wednesday, October 8th. Redburn Partners set a $220.00 price target on Danaher in a report on Wednesday, October 8th. Barclays increased their price objective on Danaher from $225.00 to $250.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 22nd. Finally, The Goldman Sachs Group started coverage on Danaher in a research note on Tuesday, December 9th. They set a “buy” rating and a $265.00 target price on the stock. Twenty-one investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $246.79.

Insider Transactions at Danaher

In related news, SVP Georgeann Couchara sold 5,174 shares of the business’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the completion of the transaction, the senior vice president owned 2,625 shares of the company’s stock, valued at approximately $552,352.50. The trade was a 66.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Teri List sold 3,298 shares of the firm’s stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $226.50, for a total value of $746,997.00. Following the completion of the sale, the director directly owned 20,762 shares in the company, valued at $4,702,593. This trade represents a 13.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 30,248 shares of company stock worth $6,609,663. Company insiders own 11.20% of the company’s stock.

Danaher Stock Down 2.4%

Shares of Danaher stock opened at $226.70 on Monday. The stock has a 50-day simple moving average of $218.51 and a 200-day simple moving average of $205.90. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $258.23. The firm has a market cap of $160.13 billion, a price-to-earnings ratio of 46.74, a P/E/G ratio of 4.39 and a beta of 0.89. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.10.

Danaher (NYSE:DHR) last announced its earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. The firm had revenue of $6.05 billion during the quarter, compared to analysts’ expectations of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The company’s revenue was up 4.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.71 earnings per share. On average, equities research analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Friday, December 26th will be issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, December 26th. Danaher’s dividend payout ratio is 26.39%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.